Table 3.
Association between MCT4 and MCT1 immunoexpressions in urothelial bladder cancer tissue sections, under different conditions, and the clinicopathological parameters.
| |
|
|
MCT4 – TH and MCT4 – TS |
MCT4 – TH and MCT1 – TN |
MCT4 – TS vs MCT1 – TN |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinicopathological parameter | n | Negative (%) | Positive(%) | pa | Negative (%) | Positive (%) | pa | Negative (%) | Positive (%) | pa | |
| TNM stage | pTa, pT1, pTis | 45 | 29 (64.4) | 16 (35.6) | 0.002 | 34 (75.6) | 11 (24.4) | 0.000 | 26 (57.8) | 19 (42.2) | 0.000 |
| pT2 | 16 | 4 (25.0) | 12 (75.0) | 10 (62.5) | 6 (37.5) | 3 (18.8) | 13 (81.3) | ||||
| pT3, pT4 | 50 | 16 (32.0) | 34 (68.0) | 15 (30.0) | 35 (70.0) | 11 (22.0) | 39 (78.0) | ||||
| Grade and Type of Lesion | NMIP UC, LG | 10 | 8 (80.0) | 2 (20.0) | 0.002 | 9 (90.0) | 1 (10.0) | 0.001 | 7 (70.0) | 3 (30.0) | 0.001 |
| NMIP UC, HG | 31 | 18 (58.1) | 13 (41.9) | 23 (74.2) | 8 (25.8) | 17 (54.8) | 14 (45.2) | ||||
| NMI UC in situ | 4 | 3 (75.0) | 1 (25.0) | 2 (50.0) | 2 (50.0) | 2 (50.0) | 2 (50.0) | ||||
| MI UC | 66 | 20 (30.3) | 46 (69.7) | 25 (37.9) | 41 (62.1) | 14 (21.2) | 52 (78.8) | ||||
| LVI | Negative | 73 | 38 (52.1) | 35 (47.9) | 0.027 | 47 (64.4) | 26 (35.6) | 0.001 | 33 (45.2) | 40 (54.8) | 0.007 |
| Positive | 38 | 11 (28.9) | 27 (71.1) | 12 (31.6) | 26 (68.4) | 7 (18.4) | 31 (81.6) | ||||
| Loco-regional metastases | Negative | 84 | 40 (47.6) | 44 (52.4) | 0.266 | 46 (54.8) | 38 (45.2) | 0.659 | 31 (36.9) | 53 (63.1) | 0.820 |
| Positive | 27 | 9 (33.3) | 18 (66.7) | 13 (48.1) | 14 (51.9) | 9 (33.3) | 18 (66.7) | ||||
Negative, none positive; positive, one or 2 positive.
aχ2 or Fisher's exact tests.
LG, low grade; LVI, lymphovascular invasion; HG, high grade MI, muscle invasive; NMI, non-muscle invasive; NMIP, non-muscle invasive papillary; TN- tumor normoxia; TH- tumor hypoxia; TS- tumor stroma; UC- urothelial carcinoma.